Top

Published in:

01-12-2013 | Original Research

High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer

Authors: Motohiro Imano, Tatsuki Itoh, Takao Satou, Atsushi Yasuda, Kohei Nishiki, Hiroaki Kato, Osamu Shiraishi, Ying-Feng Peng, Masayuki Shinkai, Masahiro Tsubaki, Takushi Yasuda, Haruhiko Imamoto, Shozo Nishida, Yoshifumi Takeyama, Hiroshi Furkawa, Kiyokata Okuno, Hitoshi Shiozaki

Published in: Targeted Oncology | Issue 4/2013

Abstract

Intraperitoneally administrated epithelial cellular adhesion molecule (EpCAM) monoclonal antibody is a therapeutic agent in patients with malignant effusion in several types of carcinoma. However, the role of EpCAM in peritoneal metastasis (PM) lesions and primary lesions of gastric cancer (GC) is still unclear. Therefore, in this study, we investigated EpCAM expression in GC patients with PM. We investigated the expression of EpCAM in 35PM lesions and 104 biopsy samples as primary lesions. Immunohistochemical staining was performed using the Ventana Benchmark XT (Roche Diagnostics) system. EpCAM expression was evaluated by calculating the total immunostaining score, which is the product of the proportion score and the intensity score. Overexpression was defined as a total score greater than 4. All PM specimens showed overexpression of EpCAM, and GC cells in both the surface layer and the deep layer of the PM showed a high expression of EpCAM. Meanwhile, in the biopsy sample, the expression of EpCAM ranged from none to strong. The EpCAM score results for PM specimens and biopsy samples were 11.0 ± 2.0 and 6.9 ± 3.9, respectively. The difference between the scores was statistically significant (P < 0.05). The intraperitoneally administrated EpCAM antibody might have a anti-cancer effect in PM lesions of GC. Additionally, it can be assumed that only GC cells which express a high level of EpCAM might metastasize to the peritoneum.

Corley DA, Buffler PA (2001) Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 30(6):1415–1425PubMedCrossRef

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221. doi:10.1016/S1470-2045(08)70035-4 PubMedCrossRef

Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN (2000) Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88(2):358–363. doi:10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O PubMedCrossRef

Hartung G, Hofheinz RD, Dencausse Y, Sturm J, Kopp-Schneider A, Dietrich G, Fackler-Schwalbe I, Bornbusch D, Gonnermann M, Wojatschek C, Lindemann W, Eschenburg H, Jost K, Edler L, Hochhaus A, Queisser W (2005) Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie 28(6–7):347–350. doi:10.1159/000084595 PubMedCrossRef

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94(1):128–135. doi:10.1038/sj.bjc.6602924 PubMedCrossRef

Varga M, Obrist P, Schneeberger S, Muhlmann G, Felgel-Farnholz C, Fong D, Zitt M, Brunhuber T, Schafer G, Gastl G, Spizzo G (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10(9):3131–3136PubMedCrossRef

Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96(3):417–423. doi:10.1038/sj.bjc.6603494 PubMedCrossRef

Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127(9):2209–2221. doi:10.1002/ijc.25423 PubMedCrossRef

Linke R, Klein A, Seimetz D (2010) Catumaxomab: clinical development and future directions. MAbs 2(2):129–136PubMedCrossRef

10.

Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasuda A, Inoue K, Kato H, Shinkai M, Tsubaki M, Yasuda T, Imamoto H, Nishida S, Furukawa H, Takeyama Y, Okuno K, Shiozaki H (2012) A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis. Anticancer Res 32(9):4071–4075PubMed

11.

Spizzo G, Obrist P, Ensinger C, Theurl I, Dunser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G (2002) Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer 98(6):883–888. doi:10.1002/ijc.10270 PubMedCrossRef

12.

Wenqi D, Li W, Shanshan C, Bei C, Yafei Z, Feihu B, Jie L, Daiming F (2009) EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol 135(9):1277–1285. doi:10.1007/s00432-009-0569-5 PubMedCrossRef

13.

Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Perol M, Genin C (2005) Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res 11(19 Pt 1):6862–6867. doi:10.1158/1078-0432.CCR-05-0043 PubMedCrossRef

14.

Diaz-Arias AA, Loy TS, Bickel JT, Chapman RK (1993) Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases. Diagn Cytopathol 9(5):516–521PubMedCrossRef

15.

De Angelis M, Buley ID, Heryet A, Gray W (1992) Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4. Cytopathology 3(2):111–117PubMedCrossRef

16.

Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23(34):5748–5758. doi:10.1038/sj.onc.1207610 PubMedCrossRef

17.

Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ, Gillanders WE (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64(16):5818–5824. doi:10.1158/0008-5472.CAN-04-0754 PubMedCrossRef

18.

Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH, Litvinov SV (2003) Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Exp Cell Res 285(1):50–58PubMedCrossRef

19.

Du W, Ji H, Cao S, Wang L, Bai F, Liu J, Fan D (2010) EpCAM: a potential antimetastatic target for gastric cancer. Dig Dis Sci 55(8):2165–2171. doi:10.1007/s10620-009-1033-8 PubMedCrossRef

20.

Imano M, Imamoto H, Itoh T, Satou T, Peng YF, Yasuda A, Kato H, Shiraishi O, Shinkai M, Yasuda T, Takeyama Y, Okuno K, Shiozaki H (2012) Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection. J Surg Oncol 105(1):43–47PubMedCrossRef

21.

Sugarbaker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 58(2):96–107PubMedCrossRef

22.

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Canc 5:67. doi:10.1186/1476-4598-5-67 CrossRef

23.

Alkatout I, Kabelitz D, Kalthoff H, Tiwari S (2008) Prowling wolves in sheep's clothing: the search for tumor stem cells. Biol Chem 389(7):799–811. doi:10.1515/BC.2008.094 PubMedCrossRef

24.

Han ME, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, Yoon S, Baek SY, Kim BS, Kang CD, Oh SO (2011) Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci 68(21):3589–3605. doi:10.1007/s00018-011-0672-z PubMedCrossRef

Title: High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer
Authors: Motohiro Imano
Tatsuki Itoh
Takao Satou
Atsushi Yasuda
Kohei Nishiki
Hiroaki Kato
Osamu Shiraishi
Ying-Feng Peng
Masayuki Shinkai
Masahiro Tsubaki
Takushi Yasuda
Haruhiko Imamoto
Shozo Nishida
Yoshifumi Takeyama
Hiroshi Furkawa
Kiyokata Okuno
Hitoshi Shiozaki
Publication date: 01-12-2013
Publisher: Springer Paris
Published in: Targeted Oncology / Issue 4/2013
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-012-0239-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78

Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro

Prognostic and therapeutic relevance of the IGF pathway in Ewing’s sarcoma patients

Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications

Follistatin as potential therapeutic target in prostate cancer

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer